Search

Your search keyword '"Taïeb D"' showing total 405 results
Start Over Author "Taïeb D"
405 results on '"Taïeb D"'

3. Hyperparathyroïdie primaire isolée d’origine génétique : leçons d’une large série française

Author

Coppin, L., primary, Cuny, T., additional, Salim, S., additional, Le Bras, M., additional, Le Collen, L., additional, Guérin, C., additional, Favriel Trulea, M., additional, Paladino, C., additional, Chevalier, B., additional, Geslot, A., additional, Cambos, S., additional, Vital, P., additional, Raingeard, I., additional, Gilly, O., additional, Vantyghem, M.C., additional, Nunès, M.L., additional, Taïeb, D., additional, Sébag, F., additional, Cardot-Bauters, C., additional, Barlier, A., additional, Odou, M.F., additional, and Romanet, P., additional

Published
2023
Full Text
View/download PDF

22. Caractérisation des patients progressifs pendant la lutathérapie

Author

Molina, O., primary, Hindié, E., additional, Tlili, G., additional, Terrebonne, E., additional, Smith, D., additional, Gaye, D., additional, Tabarin, A., additional, Hadoux, J., additional, Walter, T., additional, Deshayes, E., additional, Courbon, F., additional, Dierickx, L., additional, Duval, M., additional, Hentic, O., additional, Laboureau, S., additional, Lacombe, M., additional, Jannin, A., additional, Do Cao, C., additional, Hautefeuille, V., additional, Taïeb, D., additional, Thuillier, P., additional, and Haissaguerre, M., additional

Published
2021
Full Text
View/download PDF

23. International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers

Author

Amar, L., Pacak, K., Steichen, O., Akker, S.A., Aylwin, SJB, Baudin, E., Buffet, A., Burnichon, N., Clifton-Bligh, R.J., Dahia, PLM, Fassnacht, M., Grossman, A.B., Herman, P., Hicks, R.J., Januszewicz, A., Jimenez, C., Kunst, HPM, Lewis, D., Mannelli, M., Naruse, M., Robledo, M., Taïeb, D., Taylor, D.R., Timmers, HJLM, Treglia, G., Tufton, N., Young, W.F., Lenders, JWM, Gimenez-Roqueplo, A.P., and Lussey-Lepoutre, C.

Subjects
Adult, Aged, Algorithms, Asymptomatic Diseases, Child, Consensus, Genetic Carrier Screening/methods, Genetic Carrier Screening/standards, Genetic Testing/standards, Germ-Line Mutation, Heterozygote, Humans, Internationality, Mass Screening/methods, Mass Screening/standards, Monitoring, Physiologic/methods, Monitoring, Physiologic/standards, Succinate Dehydrogenase/genetics
Abstract

Approximately 20% of patients diagnosed with a phaeochromocytoma or paraganglioma carry a germline mutation in one of the succinate dehydrogenase (SDHx) genes (SDHA, SDHB, SDHC and SDHD), which encode the four subunits of the SDH enzyme. When a pathogenic SDHx mutation is identified in an affected patient, genetic counselling is proposed for first-degree relatives. Optimal initial evaluation and follow-up of people who are asymptomatic but might carry SDHx mutations have not yet been agreed. Thus, we established an international consensus algorithm of clinical, biochemical and imaging screening at diagnosis and during surveillance for both adults and children. An international panel of 29 experts from 12 countries was assembled, and the Delphi method was used to reach a consensus on 41 statements. This Consensus Statement covers a range of topics, including age of first genetic testing, appropriate biochemical and imaging tests for initial tumour screening and follow-up, screening for rare SDHx-related tumours and management of elderly people who have an SDHx mutation. This Consensus Statement focuses on the management of asymptomatic SDHx mutation carriers and provides clinicians with much-needed guidance. The standardization of practice will enable prospective studies in the near future.

Published
2021

27. Consensus on molecular imaging and theranostics in neuroendocrine neoplasms

Author

Ambrosini, V. Kunikowska, J. Baudin, E. Bodei, L. Bouvier, C. Capdevila, J. Cremonesi, M. de Herder, W.W. Dromain, C. Falconi, M. Fani, M. Fanti, S. Hicks, R.J. Kabasakal, L. Kaltsas, G. Lewington, V. Minozzi, S. Cinquini, M. Öberg, K. Oyen, W.J.G. O'Toole, D. Pavel, M. Ruszniewski, P. Scarpa, A. Strosberg, J. Sundin, A. Taïeb, D. Virgolini, I. Wild, D. Herrmann, K. Yao, J.

Abstract

Nuclear medicine plays an increasingly important role in the management neuroendocrine neoplasms (NEN). Somatostatin analogue (SSA)-based positron emission tomography/computed tomography (PET/CT) and peptide receptor radionuclide therapy (PRRT) have been used in clinical trials and approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). European Association of Nuclear Medicine (EANM) Focus 3 performed a multidisciplinary Delphi process to deliver a balanced perspective on molecular imaging and radionuclide therapy in well-differentiated neuroendocrine tumours (NETs). NETs form in cells that interact with the nervous system or in glands that produce hormones. These cells, called neuroendocrine cells, can be found throughout the body, but NETs are most often found in the abdomen, especially in the gastrointestinal tract. These tumours may also be found in the lungs, pancreas and adrenal glands. In addition to being rare, NETs are also complex and may be difficult to diagnose. Most NETs are non-functioning; however, a minority present with symptoms related to hypersecretion of bioactive compounds. NETs often do not cause symptoms early in the disease process. When diagnosed, substantial number of patients are already found to have metastatic disease. Several societies' guidelines address Neuroendocrine neoplasms (NENs) management; however, many issues are still debated, due to both the difficulty in acquiring strong clinical evidence in a rare and heterogeneous disease and the different availability of diagnostic and therapeutic options across countries. EANM Focus 3 reached consensus on employing 68gallium-labelled somatostatin analogue ([68Ga]Ga-DOTA-SSA)-based PET/CT with diagnostic CT or magnetic resonance imaging (MRI) for unknown primary NET detection, metastatic NET, NET staging/restaging, suspected extra-adrenal pheochromocytoma/paraganglioma and suspected paraganglioma. Consensus was reached on employing 18fluorine-fluoro-2-deoxyglucose ([18F]FDG) PET/CT in neuroendocrine carcinoma, G3 NET and in G1-2 NET with mismatched lesions (CT-positive/[68Ga]Ga-DOTA-SSA-negative). Peptide receptor radionuclide therapy (PRRT) was recommended for second line treatment for gastrointestinal NET with [68Ga]Ga-DOTA-SSA uptake in all lesions, in G1/G2 NET at disease progression, and in a subset of G3 NET provided all lesions are positive at [18F]FDG and [68Ga]Ga-DOTA-SSA. PRRT rechallenge may be used for in patients with stable disease for at least 1 year after therapy completion. An international consensus is not only a prelude to a more standardised management across countries but also serves as a guide for the direction to follow when designing new research studies. © 2021 Elsevier Ltd

Published
2021

36. Recommandations et référentiels

Author

Salaün, P.Y., Abgral, R., Malard, O., Querellou-Lefranc, S., Quéré, G., Warski, M., Coriat, R., Hindié, E., Taieb, D., Tabarin, A., Girard, A., Grellier, J.F., Brenot-Rossi, I., Groheux, D., Rousseau, C., Déandréis, D., Alberini, J.L., Bodet-Milin, C., Itti, E., Casanovas, O., Kraeber-Bodéré, F., Moreau, P., Philip, A., Balleyguier, C., Luciani, A., and Cachin, F.

Published
2019
Full Text
View/download PDF

42. First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionuclide therapy with 177Lutetium – Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial, on behalf of the ENDOCAN RENATEN network and GTE

Author

Baudin, E., Walter, T., Docao, C., Haissaguerre, M., Hadoux, J., Taieb, D., Ansquer, C., Dierickx, L., De Mestier, L., Deshayes, E., Quak, E., and Foulon, S.

Published
2022
Full Text
View/download PDF

44. Thyroid cancer recurrence in the HiLo trial

Author

HINDIE, Elif, Taieb, David, Avram, Anca, Hindié, E, Giovanella, Luca, Taïeb, D, Avram, AM., Service de médecine nucléaire, CHU Bordeaux [Bordeaux], Service de médecine nucléaire [Marseille], and Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE)

Subjects
Oncology, medicine.medical_specialty, business.industry, Endocrinology, Diabetes and Metabolism, MEDLINE, Thyrotropin, 030204 cardiovascular system & hematology, medicine.disease, Iodine Radioisotopes, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Internal medicine, Internal Medicine, Medicine, Humans, 030212 general & internal medicine, Thyroid Neoplasms, business, Thyroid cancer, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2019

45. Value of 123I/99mTc-sestamibi parathyroid scintigraphy with subtraction SPECT/CT in primary hyperparathyroidism for directing minimally invasive parathyroidectomy

Author

Paladino, Nunzia Cinzia, Guérin, Carole, Abdullah, Ahmad Esmaeel, Taieb, David, Asseeva, Pauline, Paladino, NC, Guerin, c, Castinetti, Frederic, Vaillant-Lombard, Josiane, Abdullah, AE, Farman-Ara, Bardia, Loundou, Anderson, Sebag, Frédéric, Taïeb, D, Service de médecine nucléaire [Marseille], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Centre de recherche en neurobiologie - neurophysiologie de Marseille (CRN2M), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre d'études et de recherche sur les services de santé et la qualité de vie (CEReSS), Aix Marseille Université (AMU), Service de chirurgie générale et endocrinienne, Hôpital de la Timone [CHU - APHM] (TIMONE), Physiologie, Environnement et Génétique pour l'Animal et les Systèmes d'Elevage [Rennes] (PEGASE), Institut National de la Recherche Agronomique (INRA)-AGROCAMPUS OUEST, Imagerie MOléculaire pour applications THéranostiques personnalisées (IMOTHEP), Institut FRESNEL (FRESNEL), Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU)-École Centrale de Marseille (ECM)-Centre National de la Recherche Scientifique (CNRS)- Hôpital de la Timone [CHU - APHM] (TIMONE), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
Parathyroidectomy, endocrine system diseases, Radionuclide imaging, medicine.medical_treatment, Mini-invasive surgery, Scintigraphy, 030218 nuclear medicine & medical imaging, 03 medical and health sciences, 0302 clinical medicine, medicine, Hyperparathyroidism, medicine.diagnostic_test, business.industry, Subtraction, General Medicine, 99mTc Sestamibi, medicine.disease, 3. Good health, Parathyroid scintigraphy, 030220 oncology & carcinogenesis, Surgery, Nuclear medicine, business, Minimally invasive parathyroidectomy, Primary hyperparathyroidism, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Background Primary hyperparathyroidism/(PHPT) is one of the most common endocrinological conditions. Surgery remains the only curative option. We have evaluated the performance of double isotope 123I/99mTc-sestamibi parathyroid scintigraphy/(PS) with subtraction SPECT/CT in PHP for identifying uniglandular disease. Methods Ninety PHPT patients undergoing parathyroidectomy (December 2015–August 2016) were included. All patients were evaluated with neck ultrasound/(US), PS and SPECT/CT with a new protocol. Outcomes from imaging modalities were reported as: uniglandular disease/(UGD), multiglandular disease/(MGD), or negative, and were compared to post-operative diagnoses. Results Post-operatively, 72 and 18 patients had true UGD and MGD, respectively. Sensitivities and specificities of US, pinhole scintigraphy with subtraction, pinhole and SPECT/CT with subtraction, and all modalities combined were 91.7%/38.9%, 88.9%/72.2%, 93%/66.7% and 84.72%/77.78%, respectively: specificity of US + PS superior to US alone, p = 0.074. SPECT/CT enables reclassification of doubtful uptake foci. Conclusions Combination of neck US and PS with subtraction SPECT/CT offers a higher specificity for guiding towards minimally invasive parathyroidectomy.

Published
2019

46. 887O First multicentric randomized phase II trial investigating the antitumor efficacy of peptide receptor radionucleide therapy with 177Lutetium-Octreotate (OCLU) in unresectable progressive neuroendocrine pancreatic tumor: Results of the OCLURANDOM trial

Author

Baudin, E., Walter, T.A., Beron, A., Smith, D., Hadoux, J., Lachachi, C., Taieb, D., Ansquer, C., Dierickx, L.O., de Mestier du Bourg, L., Deshayes, E., Quak, E., Dahan, L., Guimbaud, R., Touchefeu, Y., Haissaguerre, M., Do Cao, C., Lombard Bohas, C., Attard, M., and Foulon, S.

Published
2022
Full Text
View/download PDF

50. ParaPET, a new statistical approach to derive 3D maps of FDG-PET kinetic parameters

Author

Colard, E, Padovani, L, Delcourt, S, Thureau, S, Farman-Ara, B, Gouel, P, Gardin, I, Vera, P, Taïeb, D, Barbolosi, D, Hapdey, S, Equipe Quantification en Imagerie Fonctionnelle (QuantIF-LITIS), Laboratoire d'Informatique, de Traitement de l'Information et des Systèmes (LITIS), Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Institut National des Sciences Appliquées (INSA)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Université Le Havre Normandie (ULH), Normandie Université (NU)-Institut national des sciences appliquées Rouen Normandie (INSA Rouen Normandie), Normandie Université (NU), Service de médecine nucléaire [Rouen], CRLCC Haute Normandie-Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Service de Radiothérapie, APHM, Hôpital de la Timone, Marseille, Hôpital de la Timone [CHU - APHM] (TIMONE), Département de radiothérapie et de physique médicale, and Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel)

Subjects
[SDV]Life Sciences [q-bio], [SPI.SIGNAL]Engineering Sciences [physics]/Signal and Image processing, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results